AR119496A1 - Proteínas de unión a antígeno anti-il13 - Google Patents
Proteínas de unión a antígeno anti-il13Info
- Publication number
- AR119496A1 AR119496A1 ARP200102098A ARP200102098A AR119496A1 AR 119496 A1 AR119496 A1 AR 119496A1 AR P200102098 A ARP200102098 A AR P200102098A AR P200102098 A ARP200102098 A AR P200102098A AR 119496 A1 AR119496 A1 AR 119496A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- light chain
- directed against
- antigen
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a anticuerpos dirigidos contra la IL-13 y a los usos de dichos anticuerpos. Por ejemplo, de acuerdo con la presente, se proporcionan anticuerpos monoclonales humanos dirigidos contra la IL-13. Se proporcionan secuencias polinucleotídicas aisladas que codifican, y secuencias de aminoácidos que comprenden, moléculas de inmunoglobulina de cadena pesada y ligera, en particular secuencias correspondientes a secuencias de cadena pesada y ligera contiguas que abarcan las regiones marco conservadas (FR) y/o regiones determinantes de la complementariedad (CDR). Adicionalmente, también se proporcionan métodos de uso de estos anticuerpos para tratar pacientes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962879335P | 2019-07-26 | 2019-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR119496A1 true AR119496A1 (es) | 2021-12-22 |
Family
ID=72139660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200102098A AR119496A1 (es) | 2019-07-26 | 2020-07-27 | Proteínas de unión a antígeno anti-il13 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220281966A1 (es) |
EP (1) | EP4004041A1 (es) |
JP (1) | JP2022542890A (es) |
AR (1) | AR119496A1 (es) |
AU (1) | AU2020323901A1 (es) |
CA (1) | CA3148591A1 (es) |
MX (1) | MX2022000988A (es) |
TW (1) | TW202118783A (es) |
UY (1) | UY38807A (es) |
WO (1) | WO2021021676A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023166418A2 (en) * | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
WO2024097104A1 (en) * | 2022-10-31 | 2024-05-10 | Amgen Inc. | Methods of antibody characterization |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0350973B1 (de) | 1983-09-26 | 1997-11-05 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE352613T1 (de) | 1995-08-29 | 2007-02-15 | Kirin Brewery | Chimäres tier und methode zu dessen herstellung |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US7254167B2 (en) | 1998-10-30 | 2007-08-07 | Broadcom Corporation | Constellation-multiplexed transmitter and receiver |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
CA2478547C (en) | 2001-12-03 | 2011-09-20 | Abgenix, Inc. | Identification of high affinity molecules by limited dilution screening |
US8486859B2 (en) | 2002-05-15 | 2013-07-16 | Bioenergy, Inc. | Use of ribose to enhance plant growth |
JP2008520684A (ja) * | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Il−13に対する完全ヒトモノクローナル抗体 |
US8234145B2 (en) | 2005-07-12 | 2012-07-31 | International Business Machines Corporation | Automatic computation of validation metrics for global logistics processes |
US8430938B1 (en) | 2006-07-13 | 2013-04-30 | The United States Of America As Represented By The Secretary Of The Navy | Control algorithm for autothermal reformer |
JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
US8464584B2 (en) | 2007-10-19 | 2013-06-18 | Food Equipment Technologies Company, Inc. | Beverage dispenser with level measuring apparatus and display |
US8376279B2 (en) | 2008-01-23 | 2013-02-19 | Aurora Flight Sciences Corporation | Inflatable folding wings for a very high altitude aircraft |
MY152352A (en) | 2009-03-04 | 2014-09-15 | Nissan Motor | Exhaust gas purifying catalyst and method for manufacturing the same |
US8463191B2 (en) | 2009-04-02 | 2013-06-11 | Qualcomm Incorporated | Beamforming options with partial channel knowledge |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US10105142B2 (en) | 2014-09-18 | 2018-10-23 | Ethicon Llc | Surgical stapler with plurality of cutting elements |
WO2016113217A1 (en) * | 2015-01-12 | 2016-07-21 | Medimmune Limited | Il-13 binding proteins and uses thereof |
-
2020
- 2020-07-24 WO PCT/US2020/043607 patent/WO2021021676A1/en unknown
- 2020-07-24 CA CA3148591A patent/CA3148591A1/en active Pending
- 2020-07-24 AU AU2020323901A patent/AU2020323901A1/en active Pending
- 2020-07-24 EP EP20757711.5A patent/EP4004041A1/en active Pending
- 2020-07-24 MX MX2022000988A patent/MX2022000988A/es unknown
- 2020-07-24 JP JP2022504603A patent/JP2022542890A/ja active Pending
- 2020-07-24 US US17/630,437 patent/US20220281966A1/en active Pending
- 2020-07-27 UY UY0001038807A patent/UY38807A/es unknown
- 2020-07-27 AR ARP200102098A patent/AR119496A1/es unknown
- 2020-07-27 TW TW109125320A patent/TW202118783A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3148591A1 (en) | 2021-02-04 |
US20220281966A1 (en) | 2022-09-08 |
MX2022000988A (es) | 2022-05-03 |
TW202118783A (zh) | 2021-05-16 |
EP4004041A1 (en) | 2022-06-01 |
JP2022542890A (ja) | 2022-10-07 |
UY38807A (es) | 2021-02-26 |
AU2020323901A1 (en) | 2022-02-24 |
WO2021021676A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
PE20211491A1 (es) | PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS | |
CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
ATE492563T1 (de) | Vollständige humane monoklonale antikörper gegen il-13 | |
UY30260A1 (es) | Anticuerpos dirigidos contra upar y usos de los mismos | |
CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
UY27537A1 (es) | "anticuerpos para cd40" | |
UY29288A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
UY29573A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
AR058322A1 (es) | Proteinas de union especificas de factores de crecimiento tipo insulina y usos de las mismas | |
AR119496A1 (es) | Proteínas de unión a antígeno anti-il13 | |
PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
UY30524A1 (es) | Anticuerpos dirigidos a avb(beta)6 y sus usos | |
AR118763A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
CO2022006909A2 (es) | Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso | |
EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
AR093671A1 (es) | Anticuerpos monoclonales contra una proteina activada c (apc) | |
EA202092595A1 (ru) | Антитела к siglec-7 и способы их применения | |
DOP2020000005A (es) | ANTICUERPOS CONTRA MAdCAM |